CohBar's Acquisition Partner Touts Encouraging Data From Personalized Cancer Vaccine
CohBar's Acquisition Partner Touts Encouraging Data From Personalized Cancer Vaccine
CohBar的收購合作伙伴吹捧來自個性化癌症疫苗的令人鼓舞的數據
- Morphogenesis Inc and CohBar Inc (NASDAQ:CWBR) announced initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol-directed IFx-Hu2.0 therapy for Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) patients who exhibited primary resistance to ICIs.
- Related: CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
- IFx-Hu2.0 is Morphogenesis' lead personalized cancer vaccine candidate designed to overcome primary resistance to checkpoint inhibitors.
- The ongoing Phase 1b study evaluates IFx-Hu2.0 in a two-stage study design to assess the safety and to examine the effects of repeated weekly dosing for up to 3 weeks on the magnitude of the ensuing systemic immune response to determine the optimal dose and schedule for a planned Phase 2/3 registration directed trial.
- Four of 5 (80%) patients with advanced MCC and 1 of 2 (50%) patients with cSCC, or 5 of 7 total (71%), experienced objective anti-tumor responses to ICI rechallenge in this setting, with a duration of response ongoing in 4 patients and one response lasting 23 months.
- Based on the positive preliminary results, an additional 11 patients are planned for enrollment in the expansion stage of the Phase 1b study using the weekly x 3 dosing schedule.
- Additional exploratory/biomarker analyses are planned.
- Price Action: CWBR shares are down 1.37% at $2.77 on the last check Monday.
- Morphogen 和 CohBar Inc 納斯達克股票代碼：CWBR）公佈了針對對ICI表現出主要耐藥性的晚期默克爾細胞癌（MCC）和皮膚鱗狀細胞癌（csCC）患者進行協議指導的ifx-HU2.0治療後對ICI進行重新挑戰的抗腫瘤反應的探索性分析的初步結果。
- 相關： CohBar 股票翻了一番：公司同意與 Morphogenesis 合併，以推進後期腫瘤候選藥物的發展
- ifx-HU2.0是Morphogenesis的主要個性化癌症候選疫苗，旨在克服對檢查點抑制劑的主要耐藥性。
- 正在進行的1b期研究在兩階段研究設計中評估了ifx-hu2.0，以評估安全性，並檢查每週重複給藥長達3周對隨後的全身免疫反應強度的影響，以確定計劃中的2/3期註冊定向試驗的最佳劑量和時間表。
- 在這種情況下，5名晚期MCC患者中有4名（80％）和2名（50％）csCC患者中有1名（佔71％），即總共7名患者中有5名（71％）對ICI再挑戰有客觀的抗腫瘤反應，4名患者的緩解持續時間持續，一項反應持續23個月。
- 根據積極的初步結果，計劃使用每週x3的給藥時間表，在1b期研究的擴展階段再招收11名患者。
- 計劃進行更多的探索性/生物標誌物分析。
- 價格走勢： 在週一的最後一張支票中，CWBR股價下跌1.37％，至2.77美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。